贾欣欣,程燕,孟恒,姜珍,崔艳,郭兴杰
JIA Xin-xin,CHENG Yan,MENG Heng,JIANG Zhen,CUI Yan,GUO Xing-jie(School of Pharmacy

• 1:沈阳药科大学药学院

摘要(Abstract)：

目的建立测定血浆中兰索拉唑对映体浓度的高效毛细管电泳分析方法,并用于兰索拉唑在人体内立体选择性药代动力学研究。方法用乙醚作提取溶剂提取血浆中兰索拉唑。采用高效毛细管电泳法测定6名健康男性受试者经口给予兰索拉唑片后不同时刻血浆中药物对映体浓度,绘制血药浓度-时间曲线,并计算主要药动学参数。结果 S—与R—兰索拉唑对映体的主要药动学参数如下:ρmax分别为(0.538±0.039)mg.L-1和(1.050±0.250)mg.L-1,tmax为(1.8±0.7)h和(1.8±0.7)h,t1/2分别为(1.6±0.7)h和(2.7±1.0)h,用梯形法计算,AUC0-t分别为(1.49±0.36)mg.h.L-1和(4.35±1.52)mg.h.L-1。结论兰索拉唑两对映体在人体内的代谢过程具有立体选择性。
Objective To establish a method of capillary electrophoresis for the determination of lansoprazole in human plasma,and study the enantioselectivity of lansoprazole.Methods Human plasma was extracted using ether.The concentration of lansoprazole enantiomers in plasma was determined by HPCE after oral administrated of rac-lansoprazole by six healthy volunteers,then the concentration-time curves were plotted and the main pharmacokinetic parameters were calculated,respectively.Results The main pharmacokinetic parameters of S-lansoprazole and R-lansoprazole were as follows:ρmax were(0.538±0.039)mg · L-1 and(1.050±0.250)mg · L-1,tmax were(1.8±0.7)h and(1.8±0.7)h,t1/2 were(1.6±0.7)h and(2.7±1.0)h,AUC0-t were(1.49±0.36)mg · h · L-1 and(4.35±1.52)mg · h · L-1,AUC0-∞ were(1.67±0.44)mg · h · L-1 and(5.02±1.90)mg · h · L-1,respectively.Conclusions The metabolic process of the two enantiomers of lansoprazole is enantioselective.

关键词(KeyWords)： 兰索拉唑;高效毛细管电泳;手性分离;人血浆
lansoprazole;high performance capillary electrophoresis;chiral separation;human plasma

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 贾欣欣,程燕,孟恒,姜珍,崔艳,郭兴杰
JIA Xin-xin,CHENG Yan,MENG Heng,JIANG Zhen,CUI Yan,GUO Xing-jie(School of Pharmacy

DOI: 10.14066/j.cnki.cn21-1349/r.2012.07.014

参考文献(References)：

• [1]SHIN J M,MUNSON K,VAGIN O,et al.The gastricHK-ATPase:structure,function,and inhibition[J].Pflugers Arch-Eur J Physiol,2009,457:609-622.
• [2]简文娟,李刚.兰索拉唑注射剂治疗上消化道大出血的疗效观察[J].西北药学杂志,2008,23(5):320-321.
• [3]MIURA M,TADA H,YASUI F N,et al.Pharmacoki-netic differences between the enantiomers of lanso-prazole and its metabolite,5-hydroxylansoprazole,in re-lation to CYP2C19 genotypes[J].Eur J Clin Pharma-col,2004,60:623-628.
• [4]MIURA M.Enantioselective disposition of lansoprazoleand rabeprazole in human plasma[J].YakugakuZasshi,2006,126(6):395-402.
• [5]CIRILLI R,FERRETTI R,GALLINELLA B,et al.De-velopment and validation of an enantioselective andchemoselective HPLC method using a Chiralpak IA col-umn to simultaneously quantify(R)-(+)-and(S)-(-)-lansoprazole enantiomers and related impurities[J].J Pharmaceut Biomed,2009,50:9-14.
• [6]BARREIRO J C,VANZOLINI K L,CASS Q B.Directinjection of native aqueous matrices by achiral–chiralchromatography iontrap mass spectrometry for simulta-neous quantification of pantoprazole and lansoprazoleenantiomers fractions[J].J Chromatogr A,2011,1218:2865-2870.
• [7]关瑾,杨晶,石爽,等.磺丁基醚-β-环糊精手性流动相添加剂法分离兰索拉唑对映体[J].分析试验室,2009,28(2):91-93.
• [8]TORIBIO L,DEL NOZAL M J,BERNAL J L,et al.Comparative study of the enantioselective separation ofseveralantiulcer drugs by high-performance liquid chro-matography and supercritical fluid chromatography[J].J Chromatogra A,2005,1091:118-123.
• [9]EBERLE D,HUMMEL R P,KUHN R.Chiral resolutionof pantoprazole sodium and related sulfoxides by com-plex formation with bovine serum albumin in capillaryelectrophoresis[J].J Chromatogr A,1997,759:185-192.
• [10]NEVADO J J B,PENALVO G C,SANCHEZ J C J,etal.Optimisation and validation of a new CE method forthe determination of lansoprazole enantiomers in phar-maceuticals[J].Electrophoresis,2009,30:2940-2946.
• [11]张悦,张爱丽,李穆琼,等.兰索拉唑片的生物等效性研究[J].医药导报,2011,30(6):702-705.
• [12]赵旭,陈晓辉,房丽娜,等.兰索拉唑分别与铝碳酸镁、莫沙比利合用的大鼠体内药动学研究[J].中南药学,2009,7(5):349-352.
• [13]刘爱民,李健和,曹俊华,等.兰索拉唑肠溶胶囊在健康人体中的生物等效性研究[J].中国医药导报,2009,6(10):13-15.